Biogen


Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

History

Biogen was founded in 1978 in Geneva by several prominent biologists, including Kenneth Murray of the University of Edinburgh, Phillip Allen Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard, Heinz Schaller, University of Heidelberg and Charles Weissmann, University of Zurich. Gilbert and Sharp were subsequently honored with Nobel Prizes: Gilbert was recognized in 1980 with the Nobel Prize in Chemistry for his work in understanding DNA sequencing, while Sharp received the Nobel Prize in Physiology or Medicine in 1993 for his discovery of split genes.
In 2003, Biogen merged with San Diego, California-based IDEC Pharmaceuticals and adopted the name Biogen Idec. After the merger, Biogen Idec became the 3rd largest Biotechnology company in the world.
Following shifts in research core areas, the company has since shortened its name, reverting to simply Biogen. Biogen stock is a component of several stock indices such as the S&P 100, S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB.
In May 2006, the company announced it would acquire cancer specialist, Conforma Therapeutics for $250 million. Later in the same month, the company announced its intention to acquire Fumapharm AG, consolidating ownership of Fumaderm and BG-12, an oral fumarate, which is being studied for the treatment of multiple sclerosis and psoriasis.
In January 2007, the company announced it would acquire Syntonix Pharmaceuticals for up to $120 million, gaining Syntonix's lead product for hemophilia B as well as the technology for developing inhalable treatments.
In February 2013, Bloomberg broke the news that Biogen was planning to pay Elan $3.25 billion for the full rights to Tysabri, used to treat multiple sclerosis.
In January 2015, the company announced that it would acquire Convergence Pharmaceuticals for up to $675 million, with the acquisition aiming to accelerate the development of Convergence's pipeline, in particular CNV1014802 – a Phase II small molecule sodium channel blocking candidate. In October 2015, the company announced that it would lay off 11% of its workforce, effective immediately.
In March 2019, Biogen announced it would acquire Nightstar Therapeutics for $25.50 per share. Nightstar focus on adeno-associated virus based gene-therapies for inherited retinal disorders. With a setback in their Alzheimer's drug research, in March 2019 Biogen's shares fell sharply. It ended the trial of its drug aducanumab, which it was making along with Eisai. In October 2019, however, they announced that they would pursue FDA approval for aducanumab together with Eisai.
In February 2020, Biogen and Sangamo Therapeutics announced a global licensing deal to develop compounds for neuromuscular and neurological diseases.

Bioverativ

In May 2016, the company announced that it would spin off its hemophilia drug business into a public company. In August, the company announced that the spun off company would be called Bioverativ, in order to show heritage with Biogen. The company would trade on the NASDAQ exchange under the ticker symbol BIVV and would look to be spun off in early 2017. Bioverativ was acquired by Sanofi in 2018.

Acquisition history

The following is an illustration of the company's major mergers and acquisitions and historical predecessors :

Finances

For the fiscal year 2017, Biogen reported earnings of US$2.539 billion, with an annual revenue of US$12.274 billion, an increase of 7.2% over the previous fiscal cycle. Biogen's shares traded at over $289 per share, and its market capitalization was valued at over US$63 billion in November 2018. The company ranked 245 on the 2018 Fortune 500 list of the largest United States corporations by revenue.
YearRevenue
in mil. USD$		Net income
in mil. USD$		Total Assets
in mil. USD$		Price per Share
in USD$		Employees
20052,4231618,38239.89
20062,6832188,55342.39
20073,1726388,62952.16
20084,0987838,47951.09
20094,3779708,55245.11
20104,7161,0058,09251.95
20115,0491,2349,05084.78
20125,5161,38010,130125.83
20136,9321,86211,863198.436,850
20149,7032,93514,315293.107,550
201510,7643,54719,505324.997,350
201611,4493,70322,877258.277,400
201712,2742,53923,653289.197,300

Products

TherapyIndication Year Approved Year Approved Additional Information
ALPROLIX™ Control and prevention of bleeding episodes, perioperative management and routine prophylaxis in adults and children with hemophilia B20141993Also approved in Canada and Australia.
Biogen and Swedish Orphan Biovitrum are collaborators in the development and commercialization of ALPROLIX.
AVONEX® Relapsing forms of multiple sclerosis19961997Includes the AVONEX PEN auto-injector and the AVOSTARTGRIP titration kit approved in the U.S. in 2012.
ELOCTATE™ Control and prevention of bleeding episodes, perioperative management and routine prophylaxis in adults and children with hemophilia A20141999Biogen and Swedish Orphan Biovitrum are collaborators in the development and commercialization of ELOCTATE.
FAMPYRA Multiple sclerosis 20102011Marketed by Biogen in markets outside of the United States.
Commercialized in the United States as AMPYRA Extended Release Tablets, by Acorda Therapeutics.
FUMADERM Psoriasis German use1994 Approved in Germany.
Acquired in acquisition of Fumapharm AG in 2006.
GAZYVA Chronic lymphocytic leukemia20132014The first medicine approved with the FDA's Breakthrough Therapy Designation and is also currently in Phase 3 trials for NHL and diffuse large B-cell lymphoma.
Currently commercialized in the United States by Genentech, a wholly owned subsidiary of Roche.
SPINRAZA Spinal muscular atrophy20162017The first drug approved for the treatment of spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals.
PLEGRIDY Relapsing forms of multiple sclerosis20142014
RITUXAN Non-Hodgkin lymphoma
Anti-TNF Refractory Rheumatoid Arthritis
ANCA-Associated Vasculitis
Chronic lymphocytic leukemia		1997
2006
2011		1998 The first monoclonal antibody for cancer developed by IDEC, prior to merging with Biogen.
Currently commercialized by Roche and its subsidiary, Genentech.
TECFIDERA Relapsing forms of multiple sclerosis20132014
TYSABRI Relapsing-remitting multiple sclerosis2004 Re-introduced in 20062006Full rights purchased from partner Elan in 2013.

Pipeline

Biogen has focused its R&D efforts on the discovery and development of treatments for patients with high unmet medical needs in the areas of neurology, hematology and immunology.
Investigational MS medicines:
Biogen has several candidates in Phase 1 and 2 clinical trials in neurodegenerative and immunological diseases including MS, neuropathic pain, spinal muscular atrophy and lupus nephritis:
Biogen also has several development agreements in place with Ionis Pharmaceuticals to collaborate to leverage antisense technology in advancing the treatment of neurological disorders.
In February 2012, Biogen formalized a joint venture with Samsung, creating Samsung Bioepis. This joint venture brings Biogen's expertise and capabilities in protein engineering, cell line development, and recombinant biologics manufacturing to position the joint venture so Biogen can participate in the emerging market for biosimilars.
In early 2014, Biogen entered into an agreement with Eisai, Inc., to jointly develop and commercialize two of their candidates for Alzheimer's disease, which have the potential to reduce Aβ plaques that form in the brains of patients, as well as to slow the formation of new plaques, potentially improving symptoms and suppressing disease progression.
Biogen also has since 2015 an agreement with AGTC for the development of gene therapy for ophthalmologic diseases such as X-linked retinoschisis and X-linked Retinitis pigmentosa, and up to three other genetic diseases. To this aim, Biogen paid AGTC $124 million, including an equity investment of $30 million, and up to 1,1 billion in future milestones.
In March 2019, Biogen halted Phase 3 trials of Alzheimer's disease drug Aducanumab after "an independent group's analysis show that the trials were unlikely to 'meet their primary endpoint.'" However, in October 2019 they reversed their plans and said that they would be pursuing US FDA approval for Aducanumab. The reversal came after Biogen said a new analysis of a larger patient pool showed promising results. In July 2020, Biogen completed submission of a Biologics license application to the FDA for review, and requested accelerated review.